Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ) just unveiled an update.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced an extraordinary general meeting (EGM) to be held on July 21, 2025, to discuss and approve a merger agreement with Sunshine Lake Pharma Co., Ltd. The meeting will also consider the approval of a special dividend of HK$1.50 per share for shareholders, excluding the offeror and its subsidiaries. The merger and dividend decisions are significant for the company’s strategic direction and may impact shareholder value.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a pharmaceutical company based in the People’s Republic of China. It is involved in the development, manufacturing, and distribution of pharmaceutical products, focusing on the Chinese market.
Average Trading Volume: 9,690,048
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.11B
For an in-depth examination of 1558 stock, go to TipRanks’ Overview page.